Enalapril Maleate and Hydrochlorothiazide Tablets
» Enalapril Maleate and Hydrochlorothiazide Tablets contain not less than 90.0 percent and not more than 110.0 percent of the labeled amounts of Enalapril Maleate (C20H28N2O5·C4H4O4) and Hydrochlorothiazide (C7H8ClN3O4S2).
Packaging and storage— Preserve in well-closed containers.
USP Reference standards 11
USP Enalaprilat RS
.
USP Enalapril Maleate RS
.
USP Hydrochlorothiazide RS
.
Identification—
A: The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay for enalapril maleate.
B: The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay for hydrochlorothiazide.
Dissolution 711
Medium: water; 900 mL.
Apparatus 2: 50 rpm.
Time: 30 minutes.
Determine the amount of C20H28N2O5·C4H4O4 dissolved, using filtered portions of the solution under test and following the Procedure for content uniformity of enalapril maleate in the test for Uniformity of dosage units, making any necessary volumetric adjustments, in comparison with a Standard solution of USP Enalapril Maleate RS having similar concentrations in the same Medium.
Determine the amount of C7H8ClN3O4S2 dissolved by employing UV absorption at the wavelength of maximum absorbance at about 320 nm and at 360 nm in 1-cm cells, on filtered portions of the solution under test, suitably diluted with Medium, in comparison with a Standard solution having a known concentration of USP Hydrochlorothiazide RS dissolved in 20 mL of methanol and diluted with Medium. Calculate the quantity, in mg, of hydrochlorothiazide dissolved by the formula:
(TC/D)(A320A360)U /(A320A360)S
in which T is the Tablet label claim, in mg, for hydrochlorothiazide; C is the concentration, in mg per mL, of hydrochlorothiazide in the Standard solution; D is the concentration, in mg per mL, of hydrochlorothiazide in the solution under test; and (A320A360)U and (A320A360)S are the differences in the absorbances at 320 and 360 nm of the solution under test and the Standard solution, respectively.
Tolerances— Not less than 80% (Q) of the labeled amount of enalapril maleate (C20H28N2O5·C4H4O4) and not less than 60% (Q) of the labeled amount of hydrochlorothiazide (C7H8ClN3O4S2) are dissolved in 30 minutes.
Uniformity of dosage units 905: meet the requirements.
procedure for content uniformity of enalapril maleate—
Buffer solution A Dissolve 136 g of monobasic potassium phosphate in 800 mL of water, adjust with phosphoric acid to a pH of 4.0, dilute with water to 1000 mL, and mix.
Buffer solution B Transfer 20.0 mL of Buffer solution A to a 1000-mL volumetric flask, dilute with water to volume, and mix.
Mobile phase Prepare a filtered and degassed mixture of water, acetonitrile, and Buffer solution A (34:15:1). Make adjustments if necessary (see System Suitability under Chromatography 621).
Standard solution Dissolve an accurately weighed quantity of USP Enalapril Maleate RS in Buffer solution B to obtain a solution having a known concentration of about 100 µg per mL.
Test solution Transfer one finely powdered Tablet to a 50-mL volumetric flask, add about 30 mL of Buffer solution B, and sonicate for 15 minutes. Shake by mechanical means for 30 minutes, dilute with Buffer solution B to volume, sonicate for 30 minutes, mix, and filter, discarding the first portion of the filtrate. Dilute a portion of the filtrate with Buffer solution B quantitatively to obtain a solution containing about 100 µg per mL.
Chromatographic system (see Chromatography 621) The liquid chromatograph is equipped with a 215-nm detector and a 4.6-mm × 20-cm column containing 10-µm packing L7 and maintained at a temperature of 80. The flow rate is about 2 mL per minute. Chromatograph the Standard solution, and record the peak responses as directed for Procedure: the capacity factor, k¢, is not less than 2.5; the column efficiency determined from the analyte peak is not less than 1000 theoretical plates; the tailing factor for the analyte peak is not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%.
Procedure Separately inject equal volumes (about 50 µL) of the Test solution and the Standard solution into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of C20H28N2O5·C4H4O4 in the Tablet taken by the formula:
(TC/D)(rU / rS)
in which T is the labeled quantity, in mg, of enalapril maleate in the Tablet; C is the concentration, in µg per mL, of USP Enalapril Maleate RS in the Standard solution; D is the concentration, in µg per mL, of enalapril maleate in the Test solution; based upon the labeled quantity per Tablet and the extent of dilution; and rU and rS are the enalapril peak responses obtained from the Test solution and the Standard solution, respectively.
procedure for content uniformity of hydrochlorothiazide—
Buffer solution A and Buffer solution B— Prepare as directed under Procedure for content uniformity of enalapril maleate.
Standard solution Transfer about 50 mg of USP Hydrochlorothiazide RS, accurately weighed, to a 200-mL volumetric flask. Add 20 mL of methanol to dissolve the material, dilute with Buffer solution B to volume, and mix to obtain a stock solution. Transfer 5.0 mL of the stock solution to a 25-mL volumetric flask, dilute with Buffer solution B to volume, and mix to obtain a solution having a known concentration of about 50 µg per mL.
Test solution Transfer 1 Tablet to a volumetric flask of a suitable size such that, when the hydrochlorothiazide is dissolved from the Tablet, a solution having a concentration of about 250 µg per mL is obtained. Add a volume of Buffer solution B equal to about half the capacity of the flask, and sonicate with occasional shaking for 15 minutes. Shake by mechanical means for 30 minutes, dilute with Buffer solution B to volume, sonicate for 30 minutes, mix, and filter, discarding the first portion of the filtrate. Transfer 5.0 mL of the clear filtrate to a 25-mL volumetric flask, dilute with Buffer solution B to volume, and mix.
Procedure Determine the absorbances of the Standard solution and the Test solution in 1-cm cells at the wavelength of maximum absorbance at about 320 nm and at 360 nm, with a suitable spectrophotometer, relative to Buffer solution B as the blank. Calculate the quantity, in mg, of C7H8ClN3O4S2 in the Tablet taken by the formula:
(TC / D)(A320A360)U /(A320A360)S
in which T is the labeled quantity, in mg, of hydrochlorothiazide in the Tablet; C is the concentration, in µg per mL, of USP Hydrochlorothiazide RS in the Standard solution; D is the concentration, in µg per mL, of hydrochlorothiazide in the Test solution, based upon the labeled quantity per Tablet and the extent of dilution; and the parenthetic expressions are the differences in absorbances of the two solutions at the wavelengths indicated by the subscripts for the Test solution (U) and the Standard solution (S), respectively.
Related compounds—
Buffer solution and Mobile phase— Proceed as directed in the Assay for enalapril maleate.
Test solution— Use the Assay preparation prepared as directed in the Assay for enalapril maleate.
Enalaprilat solution— Transfer about 10 mg of USP Enalaprilat RS, accurately weighed, to a 25-mL volumetric flask, dilute with water to volume, and mix.
Enalapril diketopiperazine solution— Carefully place about 20 mg of USP Enalapril Maleate RS in a 100-mL beaker to form a mound on the bottom of the beaker. Place the beaker on a hot plate at about one-half the maximum hot plate temperature setting. Heat for about 5 to 10 minutes until the solid is melted. Immediately remove the beaker from the hot plate, and allow to cool. [note—Avoid overheating to prevent heat-induced degradation, which would give rise to a brown color.] To the cooled residue in the beaker add 50 mL of acetonitrile, and sonicate for a few minutes to dissolve. The solution typically contains, in each mL, between 0.2 mg and 0.4 mg of enalapril diketopiperazine.
Standard solution— Transfer about 40 mg of USP Enalapril Maleate RS, accurately weighed, to a 200-mL volumetric flask, and dissolve with about 50 mL of methanol. Pipet 1 mL each of Enalaprilat solution and Enalapril diketopiperazine solution into the volumetric flask, dilute with Buffer solution to volume, and mix.
Chromatographic system (see Chromatography 621)— The liquid chromatograph is equipped with a 215-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L7. The column temperature is maintained at 65, and the flow rate is about 1.5 mL per minute. Chromatograph the Standard solution, and record the peak responses as directed for Procedure: the relative retention times are about 0.3, 0.4, and 1.0 for enalaprilat, enalapril diketopiperazine, and enalapril, respectively; the resolution, R, between any of the peaks is not less than 1.3; the column efficiency is not less than 700 theoretical plates for enalapril, 1500 for enalaprilat, and 1500 for enalapril diketopiperazine; the tailing factor is not more than 3.5; and the relative standard deviation for replicate injections is not more than 5.0% for enalaprilat and enalapril diketopiperazine and not more than 2.0% for enalapril.
Procedure— Separately inject equal volumes (about 50 µL) of the Standard solution and the Test solution into the chromatograph, record the chromatograms, and measure the responses for the peaks. Calculate the quantity, in mg, of enalaprilat (enalapril related compound A) in the portion of Tablets taken by the formula:
0.2C(rU / rS)
in which C is the concentration, in µg per mL, of enalaprilat in the Standard solution; and rU and rS are the peak responses of enalaprilat obtained from the Test solution and the Standard solution, respectively.
Calculate the quantity, in mg, of enalapril diketopiperazine in the portion of Tablets taken by the formula:
0.2C(rU / rS)
in which C is the concentration, in µg per mL, of enalapril diketopiperazine in the Standard solution; and rU and rS are the peak responses of enalapril diketopiperazine obtained from the Test solution and the Standard solution, respectively: not more than 5.0% of total related compounds is found, calculated on the basis of the portion of Tablets taken as directed under Assay for enalapril maleate.
Assay for enalapril maleate—
Buffer solution— Transfer 136 mg of monobasic potassium phosphate to a 1000-mL volumetric flask, add 800 mL of water, adjust with phosphoric acid to a pH of 2.0, dilute with water to volume, and mix.
Mobile phase— Prepare a degassed and filtered solution of Buffer solution and acetonitrile (6:4). Make adjustments if necessary (see System Suitability under Chromatography 621).
Standard preparation— Transfer about 40 mg of USP Enalapril Maleate RS, accurately weighed, to a 200-mL volumetric flask, add about 50 mL of methanol to dissolve, dilute with Buffer solution to volume, and mix.
Assay preparation— Weigh and finely powder not fewer than 20 Tablets. Transfer an accurately weighed portion of the powder, equivalent to about 40 mg of enalapril maleate, to a 200-mL volumetric flask, add about 50 mL of Buffer solution, and sonicate for 15 minutes. Add about 50 mL of methanol to the flask, sonicate for 15 minutes, dilute with Buffer solution to volume, mix, and filter.
Chromatographic system (see Chromatography 621)— The liquid chromatograph is equipped with a 215-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L7. The column temperature is maintained at 65, and the flow rate is about 1.5 mL per minute. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the column efficiency is not less than 700 theoretical plates; the tailing factor is not more than 3.5; and the relative standard deviation for replicate injections is not more than 2.0%.
Procedure— Separately inject equal volumes (about 50 µL) of the Assay preparation and the Standard preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of enalapril maleate (C20H28N2O5·C4H4O4) in the portion of Tablets taken by the formula:
200C(rU / rS)
in which C is the concentration, in µg per mL, of USP Enalapril Maleate RS in the Standard preparation; and rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively.
Assay for hydrochlorothiazide—
Buffer solution— Prepare as directed under Assay for enalapril maleate.
Mobile phase— Prepare a filtered and degassed mixture of Buffer solution and acetonitrile (9:1). Make adjustments if necessary (see System Suitability under Chromatography 621).
Standard preparation— Transfer about 20 mg of USP Hydrochlorothiazide RS, accurately weighed, to a 200-mL volumetric flask, add about 50 mL of methanol to dissolve, dilute with Buffer solution to volume, and mix.
Assay preparation— Prepare as directed for the Assay preparation under Assay for enalapril maleate, except to weigh a portion of the powdered Tablets equivalent to about 20 mg of hydrochlorothiazide.
Chromatographic system (see Chromatography 621)— The liquid chromatograph is equipped with a 310-nm detector and a 4.6-mm × 20-cm column that contains 10-µm packing L7. The column temperature is maintained at 30, and the flow rate is about 2.5 mL per minute. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the capacity factor, k¢, is not less than 2.0; the column efficiency is not less than 1000 theoretical plates; the tailing factor is not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%.
Procedure— Separately inject equal volumes (about 50 µL) of the Assay preparation and the Standard preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of hydrochlorothiazide (C7H8ClN3O4S2) in the portion of Tablets taken by the formula:
200C(rU / rS)
in which C is the concentration, in µg per mL, of USP Hydrochlorothiazide RS in the Standard preparation; and rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Please check for your question in the FAQs before contacting USP.
Topic/Question Contact Expert Committee
Monograph Sujatha Ramakrishna, Ph.D.
Scientist
1-301-816-8349
(MDCV05) Monograph Development-Cardiovascular
Reference Standards Lili Wang, Technical Services Scientist
1-301-816-8129
RSTech@usp.org
711 Margareth R.C. Marques, Ph.D.
Senior Scientist
1-301-816-8106
(BPC05) Biopharmaceutics05
USP32–NF27 Page 2250
Pharmacopeial Forum: Volume No. 33(2) Page 220
Chromatographic Column—
Chromatographic columns text is not derived from, and not part of, USP 32 or NF 27.